Valiant Laboratories Limited has authorized a ₹60 crore capital injection into its wholly owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL), to fund working capital and general corporate purposes. The Board of Directors approved the investment on August 10, 2026, alongside key governance changes including the re-appointment of Managing Director Santosh Vora and Independent Director Sonal Vira, and a strategic shift of the registered office from Mumbai to Palghar. This move strengthens the financial base of the company’s high-growth specialty chemicals arm without diluting equity control.

The investment will be executed in one or more tranches over the next 12 months, subject to VASPL’s fund requirements. Valiant Laboratories will subscribe to 1% Optionally Convertible Redeemable Preference Shares in the subsidiary. As VASPL is a related party, the transaction is conducted at arm’s length in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The parent company retains 100% shareholding, ensuring no change in the equity structure.

Leadership and Governance Updates

The Board also approved several directorship changes, all subject to Special Resolution approval at the ensuing Annual General Meeting:

• Santosh Vora: Re-appointed as Managing Director for five years, effective February 06, 2027. He holds a PGPM from ISB and has over 8 years of experience in the chemical and pharmaceutical industry.
• Sonal Vira: Re-appointed as Independent Director for a second five-year term, effective February 16, 2027. She is a Chartered Accountant with over 15 years of experience in corporate banking.
• Shantilal Vora: Continuation of directorship as Non-Executive Non-Independent Director upon attaining 75 years of age, effective November 05, 2027, in compliance with Regulation 17(1A) of the Listing Regulations.

Operational Restructuring

Valiant Laboratories approved shifting its registered office from Mulund, Mumbai, to Plot No. L-13, L-28, L-28(Pt), L-29 & L-30, MIDC Tarapur, Boisar, Palghar, Maharashtra - 401506. This change shifts jurisdiction from the Registrar of Companies, Mumbai-I, to Mumbai-II (Navi Mumbai). Concurrently, a new corporate office will open at 701, Tower B, Embassy 247 Park, LBS Road, Vikhroli (West), Mumbai, to handle administrative, management, finance, and secretarial functions.

VASPL Financial Performance

VASPL, incorporated on July 08, 2022, manufactures specialty chemicals including acetic anhydride, ketene, and diketene derivatives. The subsidiary has demonstrated rapid revenue growth since inception.

As of March 31, 2026, VASPL reported a net worth of ₹15,618.41 Lakh. The substantial increase in turnover from ₹2.02 Lakh in FY25 to ₹4,164.86 Lakh in FY26 indicates that the subsidiary has scaled operations significantly, justifying the need for additional working capital support from the parent company.

What the Numbers Show

The financial trajectory of VASPL highlights a pivot from early-stage setup to active commercial operations. With turnover jumping from negligible levels in FY24 to over ₹41 crore in FY26, the subsidiary has become a material part of the group’s operational footprint. The ₹60 crore investment represents a strategic allocation of capital to sustain this growth momentum, particularly given that VASPL’s net worth stands at approximately ₹156 crore. This suggests the parent company is leveraging its balance sheet to optimize the capital structure of its high-growth specialty chemicals arm without diluting equity ownership.

Valiant Laboratories has received an order from the Office of the Joint Commissioner, CGST & C. Ex., Navi Mumbai Commissionerate, confirming a GST demand of ₹18 Lakhs along with a penalty of ₹18 Lakhs. The order, dated May 29, 2026, also includes interest under Section 50(1) of the CGST Act, 2017, and relevant sections of the SGST Act, 2017. The financial impact stems from a Corporate Guarantee covering the period from April 2023 to March 2024.

The adjudicating authority dropped other alleged violations mentioned in the Show Cause Notice dated January 14, 2026. These included the ineligible availment of Input Tax Credit on IPO expenses of approximately ₹2.85 Crore and a turnover mismatch between Financial Statements and GST returns for FY 2021-22 of approximately ₹9.31 Crore. The total demand initially raised in the notice was ₹36 Lakhs, of which ₹18 Lakhs has been confirmed.

Details of the Order

The communication was received under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The table below outlines the key particulars of the order and the company's response.

The company has declared that the details provided in the annexure are true, correct, and complete to the best of its knowledge. Valiant Laboratories stated that it is currently evaluating all available options, including filing an appeal against the order before the appropriate authority.